British Biotech signs MMPI deal with Schering-Plough
British Biotech and Schering-Plough will develop and market, as a cancer treatment, BB's matrix metalloproteinase inhibitors (MMPIs), including Marimastat and BB-3644. Schering gets exclusive worldwide rights except in Japan and those Far Eastern countries where Tanabe Seiyaku has rights.
- Includes Equity
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com